An interventional study of Telemedicine and Standard of care in Substance Use Disorders, Hiv and Opioid Use Disorder, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham — 5 open to participants now, 5 under way, none of them phase 3. Opioid-Related Disorders · University of Alabama at Birmingham.
Among the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, this one is one of 2 that started in 2026, is one of 4 with no phase, and was the 6th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →5 of the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 19+
University of Alabama at Birmingham · Sites in United States
Ages 18–60 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–80 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 44 across the 9 interventional studies, 200 across the 1 observational. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
1 of the studies in Opioid-Related Disorders by University of Alabama at Birmingham that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07128485University of Alabama at BirminghamRemote Intervention to Prevent Overdose | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with HIV in Alabama.
The contemporary drug crisis and the COVID-19 pandemic have exposed the complex syndemics of addiction and infectious diseases: rising rates of substance use disorder (SUD) have outpaced our ability to respond with a limited healthcare workforce and public health capacity. SUD is increasing in those living with and at risk for HIV, and infectious consequences of SUD, like hepatitis C, have continued, unmitigated, in rural parts of the U.S. where many states lack Medicaid expansion, syringe service programs, and public health infrastructure to respond to the drug crisis and comorbid infections. Systemic racism and regressive policies in the Deep South criminalize people who use drugs, creating additional barriers to care, HIV prevention, and addiction treatment. As a result, people who use drugs rarely receive comprehensive addiction and HIV treatment. Yet telemedicine has the potential to overcome these barriers and bypass the constraints of a brick-and-mortar clinic to link vulnerable people, including those with HIV, to care. Although telemedicine has become mainstream in recent years, few studies have evaluated telemedicine for SUD in the Deep South from the perspective of patients and providers.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
This study's planned enrollment of 30 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
Compared within Opioid-Related Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Substance-Related Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients living with HIV and substance use, aged 18 and over. These participants are receiving services at HIV clinics in Alabama and must have reported opioid and/or stimulant misuse.
Other: Telemedicine · Other: Standard of care
Routine care administered via telemedicine
Standard of care, as received in HIV clinic settings
Percent of participants who have a follow-up healthcare visit
Follow up visit for care (either telemedicine or in person)
Time frame: 1 month, 2 months, 3 months
Plan to share: Yes — The research will comply with the NIH Data Sharing policy and will coordinate collection and sharing of key data. Data are available upon request from the public and research community after main findings are published. To request data, the investigators ask that interested parties submit a detailed description of the aims and methods of their research to the PI, including contact information from the primary requester, institutional affiliation, current CV and qualifications, sources of financial support, and conflict of interest statement. The MPIs will review requests as submitted and determine the appropriateness of the request with collaborators or if additional safeguards are needed. Upon approval, data transfer agreements must be established and proof of IRB approval from the requester's institutional IRB must be presented. Our team will comply with HIPAA and Common Rule de-identification prior to data sharing to ensure protection of study participants
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Available after studies are published and will be maintained for 5 years after study end date.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 35 months is above that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →